Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Market does know how to value biotech companies. See below

<< Previous

Bullboard Posts

Next >>

Comment by Momo25on May 28, 2024 11:28am

142 Views

Post# 36060389

RE:RE:Market does know how to value biotech companies. See below

Maybe the market got it wrong with Thera because it is hard to get it right with this kind of management. Anyway, what I try to say is don't be so excited with the current outcome, we don't even know if what they are saying is true. Only FDA validation can make thi stock more appealing .

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023